We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis’ CAR-T Cell Therapy Falters in Late-Stage Trial
Novartis’ CAR-T Cell Therapy Falters in Late-Stage Trial
Novartis said its chimeric antigen receptor T-cell (CAR-T) therapy Kymriah (tisagenlecleucel) failed to boost survival in patients with aggressive B-cell nonHodgkin lymphoma in a phase 3 study.